United States - English - NLM (National Library of Medicine)

celltrion usa, inc. - deferasirox (unii: v8g4mof2v9) (deferasirox - unii:v8g4mof2v9) - deferasirox tablets are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (ntdt) syndromes and with a liver iron concentration (lic) of at least 5 milligrams of iron per gram of liver dry weight (mg fe/g dw) and a serum ferritin greater than 300 mcg/l. the safety and efficacy of deferasirox tablets when administered with other iron chelation therapy have not been established. deferasirox tablets are contraindicated in patients with: - estimated gfr less than 40 ml/min/1.73 m2  [see dosage and administration (2.5), warnings and precautions (5.1)] ; - poor performance status [see warnings and precautions (5.1, 5.3)] ; - high-risk myelodysplastic syndromes (this patient population was not studied and is not expected to benefit from chelation therapy) ; - advance

United States - English - NLM (National Library of Medicine)

cipla usa inc. - deferasirox (unii: v8g4mof2v9) (deferasirox - unii:v8g4mof2v9) - deferasirox granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. deferasirox granules are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (ntdt) syndromes and with a liver iron concentration (lic) of at least 5 milligrams of iron per gram of liver dry weight (mg fe/g dw) and a serum ferritin greater than 300 mcg/l. the safety and efficacy of deferasirox when administered with other iron chelation therapy have not been established. deferasirox granules are contraindicated in patients with: - estimated gfr less than 40 ml/min/1.73 m2 [see dosage and administration (2.5), warnings and precautions (5.1)] ; - poor performance status [see warnings and precautions (5.1, 5.3)] ; - high-risk myelodysplastic syndromes (this patient population was not studied and is not expected to benefit from chelation therapy) ; - advanced m

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - deferasirox (unii: v8g4mof2v9) (deferasirox - unii:v8g4mof2v9) - deferasirox tablets are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (ntdt) syndromes and with a liver iron concentration (lic) of at least 5 milligrams of iron per gram of liver dry weight (mg fe/g dw) and a serum ferritin greater than 300 mcg/l. the safety and efficacy of deferasirox tablets when administered with other iron chelation therapy have not been established. deferasirox tablets are contraindicated in patients with: - estimated gfr less than 40 ml/min/1.73 m2 [see dosage and administration (2.5), warnings and precautions (5.1)] ; - poor performance status [see warnings and precautions (5.1, 5.3)] ; - high-risk myelodysplastic syndromes (this patient population was not studied and is not expected to benefit from chelation therapy) ; - advance

United States - English - NLM (National Library of Medicine)

santarus, inc. - conestat alfa (unii: 5qs67n4551) (conestat alfa - unii:5qs67n4551) - conestat alfa 2100 u - ruconest is a c1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (hae). limitation of use:  effectiveness was not established in hae patients with laryngeal attacks. pregnancy category b. studies performed in rats and rabbits at doses up to 12.5 times the human dose of 50 u/kg could not exclude an effect on embryofetal development. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, ruconest should only be used during pregnancy if clearly needed. the safety and efficacy of ruconest administration prior to or during labor and delivery have not been established. use only if clearly needed. it is not known if ruconest is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when ruconest is administered to a nursing woman. the safety and efficacy of ruconest were evaluated

United States - English - NLM (National Library of Medicine)

beaumont bio med - astacus astacus (unii: v0551986xq) (astacus astacus - unii:v0551986xq), barium iodide (unii: wkc4t7680a) (barium cation - unii:v645272hln), calcium iodide (unii: 8eki9qee2h) (calcium cation - unii:2m83c4r6zb), helianthemum canadense (unii: 46g3w789q3) (helianthemum canadense - unii:46g3w789q3), clematis recta flowering top (unii: 396421sp9f) (clematis recta flowering top - unii:396421sp9f), conium maculatum flowering top (unii: q28r5gf371) (conium maculatum flowering top - unii:q28r5gf371), iodine (un - astacus astacus 10 [hp_x] in 59.2 ml - indications: ​  for temporary relief of: enlarged and swollen glands, painful and inflamed glands of the jaw, neck, armpit and groin area. associated with viral inflammations such as colds and flu. for temporary relief of: - enlarged and swollen glands - painful and inflamed glands of the jaw, neck, and groin area associated with viral inflammations such as colds and flu.

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - ginger (unii: c5529g5jpq) (ginger - unii:c5529g5jpq) - ginger 3 [hp_x] in 1 ml

United States - English - NLM (National Library of Medicine)

beaumont bio med - cairina moschata heart/liver autolysate (unii: rn2hc612gy) (cairina moschata heart/liver autolysate - unii:rn2hc612gy), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), baptisia tinctoria root (unii: 5ef0hwi5wu) (baptisia tinctoria root - unii:5ef0hwi5wu), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), causticum (unii: dd5fo1wkfu) (causticum - unii:dd5fo1wkfu), cinchona officinalis bark (unii: s003a158sb) (cinchona officinalis bark - unii:s003a1 - cairina moschata heart/liver autolysate 35 [hp_c] in 59.2 ml - indications: for temporary relief of flu-like symptoms: • fever • fatigue • nausea • cough • runny nose • congestion • sore throat • diarrhea •headache use according to label indications and/or standard homeopathic indications. for temporary relief of: for temporary relief of flu-like symptoms: - fever - fatigue - nausea - cough - runny nose - congestion - sore throat - diarrhea - headache

United States - English - NLM (National Library of Medicine)

beaumont bio med - cairina moschata heart/liver autolysate (unii: rn2hc612gy) (cairina moschata heart/liver autolysate - unii:rn2hc612gy), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), baptisia tinctoria root (unii: 5ef0hwi5wu) (baptisia tinctoria root - unii:5ef0hwi5wu), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), solanum dulcamara top (unii: kps1b1162n) (solanum dulcamara top - unii:kps1b1162n), echinacea, unspecified (unii: 4n9p6cc1dx) (echinacea, unspeci - cairina moschata heart/liver autolysate 50 [hp_c] in 59.2 ml - indications: for temporary relief of: •body aches & pains •nasal congestion •headaches & fevers associated with the common cold and flu. use according to label indications under standard homeopathic indications. for temporary relief of: - body aches & pains - nasal congestion - headaches & fevers associated with the common cold and flu

United States - English - NLM (National Library of Medicine)

glaxosmithkline consumer healthcare holdings (us) llc - sennosides (unii: 3fyp5m0ijx) (sennosides - unii:3fyp5m0ijx) - sennosides 15 mg - stimulant laxative laxative products when abdominal pain, nausea, or vomiting are present unless directed by a doctor noticed a sudden change in bowel habits that persists over a period of 2 weeks are taking any other drug. laxatives may affect how other drugs work. take this product 2 or more hours before or after other drugs. rectal bleeding or failure to have a bowel movement occur after use of a laxative. these may be signs of a serious condition.

United States - English - NLM (National Library of Medicine)

king bio inc. - acetic acid (unii: q40q9n063p) (acetic acid - unii:q40q9n063p), amanita muscaria fruiting body (unii: dif093i037) (amanita muscaria fruiting body - unii:dif093i037), aloe (unii: v5vd430yw9) (aloe - unii:v5vd430yw9), antimony trisulfide (unii: f79059a38u) (antimony trisulfide - unii:f79059a38u), silver nitrate (unii: 95it3w8jze) (silver cation - unii:57n7b0k90a), activated charcoal (unii: 2p3vwu3h10) (activated charcoal - unii:2p3vwu3h10), silybum marianum seed (unii: u946sh95ee) (silybum marianum see - acetic acid 10 [hp_x] in 59 ml - uses temporarily relieves symptoms of upper gastrointestinal distress: heartburn, gas, nausea, bloating, slow digestion, flatulence, vomiting, sensitive stomach. uses temporarily relieves symptoms of upper gastrointestinal distress: - heartburn - gas - nausea - bloating - slow digestion - flatulence - vomiting - sensitive stomach